DOTA-(Tyr3)-octreotate Acetate Salt
Ref. 3D-CRB1001647
| 1mg | 531.00 € | ||
| 5mg | 951.00 € |
Product Information
- [DOTA]-f-C*Y-w-KTC*T-acid (acetate salt) *Disulphide Bridged[DOTA]-[D-Phe]-Cys*Tyr-[D-Trp]-Lys-Thr-Cys*-Thr-OH (acetate salt)
- Disu lphide Bridged Cys2-Cys7[DOTA]-fCYwKTCT-acid (acetate salt) Disulphide Bridged Cys2-Cys7
DOTA-conjugated somatostatin analogue for labelling with radiometals such as gallium-67 or gallium-68, indium-111, and yttrium-90. Known as DOTA-TATE, this is a useful tool in receptor-mediated tumour imaging and peptide receptor-targeted radionuclide therapy. Binding of DOTA-TATE is detected by scintigraphy even at low level. The high expression of somatostatin receptors allows their successful use as radiolabelled octreotide analogues for tumour tracing in nuclear medicine. Binding of DOTA-TATE can occur at sights of inflammatory or immunologic diseases where increased lymphocyte binding is occurring.A few radioligands have been applied on the basis of peptide receptor recognition in the past. However, an optimal radiopeptide for receptor-targeted radionuclide therapy has yet to be achieved. Ongoing developments may result in peptides more suitable for this kind of receptor-targeted radionuclide therapy. Further work with this DOTA-TATE could provide that vital inroad.
Chemical properties
Technical inquiry about: 3D-CRB1001647 DOTA-(Tyr3)-octreotate Acetate Salt
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
